Inventor
FRASER GRAEME L
BE17 patents
⚠️ This page may combine multiple inventors who share the name “FRASER GRAEME L”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
TRANZYME PHARMA INC
8 patentsUS7521420B2Apr 21, 2009
Macrocyclic antagonists of the motilin receptor
TRANZYME PHARMA INC46 citations95
US7491695B2Feb 17, 2009
Methods of using macrocyclic modulators of the ghrelin receptor
TRANZYME PHARMA INC39 citations95
US7476653B2Jan 13, 2009
Macrocyclic modulators of the ghrelin receptor
TRANZYME PHARMA INC48 citations95
US7452862B2Nov 18, 2008
Conformationally-controlled biologically active macrocyclic small molecules as motilin antagonists or ghrelin agonists
TRANZYME PHARMA INC23 citations90
US8349887B2Jan 8, 2013
Methods of treating cachexia with macrocyclic modulators of the ghrelin receptor
TRANZYME PHARMA INC11 citations83
USRE42624EAug 16, 2011
Methods of using macrocyclic modulators of the ghrelin receptor
TRANZYME PHARMA INC17 citations83
USRE42013EDec 28, 2010
Macrocyclic modulators of the ghrelin receptor
TRANZYME PHARMA INC18 citations83
US7550431B2Jun 23, 2009
Spatially-defined macrocycles incorporating peptide bond surrogates
TRANZYME PHARMA INC16 citations83
FRASER GRAEME L
2 patentsEUROSCREEN SA
2 patentsUS9475814B2Oct 25, 2016
Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof
EUROSCREEN SA7 citations80
US10065961B2Sep 4, 2018
Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof
EUROSCREEN SA2 citations68
OGEDA SA
2 patentsUS9926325B2Mar 27, 2018
NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
OGEDA SA0 citations51
US10065960B2Sep 4, 2018
NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
OGEDA SA0 citations40